View ValuationTong Ren Tang Technologies 将来の成長Future 基準チェック /16Tong Ren Tang Technologies利益と収益がそれぞれ年間12.4%と7.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に7.1% 12.2%なると予測されています。主要情報12.4%収益成長率12.25%EPS成長率Pharmaceuticals 収益成長14.9%収益成長率7.8%将来の株主資本利益率7.10%アナリストカバレッジLow最終更新日29 Apr 2026今後の成長に関する最新情報お知らせ • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.すべての更新を表示Recent updatesお知らせ • Apr 27+ 1 more updateTong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026, at 10:00 China Standard Time. Location: no. 28 tiangui avenue, daxing district, beijing Chinaお知らせ • Mar 16Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026お知らせ • Feb 06Tong Ren Tang Technologies Co. Ltd. Announces Appointment of Mr. Siu, Paul Yu Hay as Independent Non-Executive Director and Changes in Board Committee Composition, Effective February 6, 2026Tong Ren Tang Technologies Co. Ltd. announced that, following the extraordinary general meeting held on February 6, 2026, announced that, with effect from 6 February 2026, Mr. Siu, Paul Yu Hay has been appointed as an independent non-executive Director of the ninth session of the Board. The resignation of Mr. Li Siu Bun as an independent non-executive Director has also taken effect from the same date. Mr. Siu, Paul Yu Hay will enter into a director's service contract with the Company for a term commencing from the date of his appointment (i.e. 6 February 2026) and until the end of this session of the Board, subject to re-election at the end of the term. The resignation of Mr. Li Siu Bun as the chairman of the Audit Committee and a member of each of the Remuneration Committee and the Strategy and Planning Committee has also taken effect on 6 February 2026. The Board further resolved on 6 February 2026 to appoint Mr. Siu, Paul Yu Hay as the chairman of the Audit Committee, and a member of the Remuneration Committee and the Strategy and Planning Committee, all with effect from the same date.お知らせ • Jan 14Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Li Siu Bun from the Positions as an Independent Non-Executive Director, Chairman of the Audit Committee of the Board and A Member of Each of the Remuneration Committee of the Board and the Strategy and Planning CommitteeOn 13 January 2026, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Li Siu Bun, informing the Board of his resignation from the positions as an independent non-executive Director, chairman of the audit committee of the Board and a member of each of the remuneration committee of the Board and the strategy and planning committee of the Board due to work adjustments. The aforesaid resignation of Mr. Li will take effect upon the new independent non-executive Director being elected by the shareholders of the Company at the general meeting to be held in due course.お知らせ • Dec 31Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. held an extraordinary general meeting on December 30, 2025, at which the appointment of Ms. Du Xin as a non-executive Director of the ninth session of the Board of the Company was approved and confirmed. The resignation of Mr. Chen Fei as a non-executive Director has also taken effect from the same date. Ms. Du Xin will enter into a director’s service contract with the Company for a term commencing from the date of her appointment, December 30, 2025, and until the end of this session of the Board, subject to re-election at the end of the term. Ms. Du Xin’s remuneration for her services as a non-executive Director is nil, which is determined by the Board with reference to the recommendation from the remuneration committee of the Board, having taken into account her duties and responsibilities with the Company and the prevailing market conditions. As at the date of this announcement, Ms. Du Xin’s biographical details remain unchanged from those stated in the circular dated December 1, 2025 save as disclosed in this announcement. As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza, Mr. Zhan Yuan Jing and Mr. Li Siu Bun as independent non-executive Directors, and Mr. Zhu Dong Sheng as employee Director.お知らせ • Nov 28+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Executive Changes, Effective November 28, 2025The board of directors (the "Board") of Tong Ren Tang Technologies Co. Ltd. (the "Company") hereby announces that, with effect from 28 November 2025, (i) Mr. Li Yijun ("Mr. Li") has resigned as the company secretary of the Company, the secretary of the Board, and the authorised representative (the "Authorised Representative") under the Rule 3.05 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") of the Company due to his family reasons; and (ii) Ms. Yung Mei Yee ("Ms. Yung") has ceased to serve as the agent for acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent") due to work adjustment. Both Mr. Li and Ms. Yung have confirmed that they have no disagreement with the Board and there is no matter relating to their resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board also announced that, with effect from 28 November 2025, (i) Ms. Ma Wing Yee ("Ms. Ma") has been appointed as the company secretary of the Company, the Authorised Representative and the Process Agent; and (ii) Mr. Han Guan Zhao ("Mr. Han") has been appointed as the secretary of the Board. Ms. Ma is an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited and has over 10 years of experience in corporate governance and company secretarial practice in listed companies on the Stock Exchange. She is currently the company secretary or joint company secretary of a few listed companies on the Stock Exchange. Ms. Ma obtained a bachelor's degree in Arts from the University of Hong Kong. She is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Mr. Han, aged 46, is a corporate legal adviser with a postgraduate qualification. He formerly served as the office senior legal affairs manager and manager of the legal affairs department of COFCO Feed Co. Ltd. Mr. Han joined the Company in December 2019, he currently serves as deputy general manager, general legal counsel and chief compliance officer of the Company.お知らせ • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2025 Results on Aug 26, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Jun 12+ 1 more updateTong Ren Tang Technologies Co. Ltd. Approves Final Dividend for the Year Ended 31 December 2024, Payable on 11 August 2025Tong Ren Tang Technologies Co. Ltd. announced at annual general meeting held on June 12, 2025, the shareholders approved the proposal of payment of a final dividend of RMB 0.18 (equivalent to HKD 0.196600) (tax inclusive) per share for the year ended 31 December 2024, will be paid on 11 August 2025 to the Shareholders whose names appear on the registers of members of the Company on 23 June 2025.お知らせ • May 20Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025, at 13:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, beijing, prc., Chinaお知らせ • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025お知らせ • Oct 29Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Yung Mei Yee as Joint Company SecretaryThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that, due to work adjustment, Ms. Yung Mei Yee ("Ms. Yung") has resigned as the joint company secretary of the Company with effect from 29 October 2024. Ms. Yung has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Following the resignation of Ms. Yung, Mr. Li Yijun, the other Joint Company Secretary, who possess the qualifications and experience of company secretary as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, will remain in office and act as the sole company secretary of the Company with effect from 29 October 2024.お知らせ • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2024 Results on Aug 30, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Jun 13+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Payment of Final Dividend for the Year Ended 31 December 2023, Payable on 09 August 2024Tong Ren Tang Technologies Co. Ltd. announced that at its AGM held on June 12, 2024, To consider and, if thought fit, to approve the proposal of payment of a final dividend of RMB 0.18 (tax inclusive) per share for the year ended 31 December 2023. Ex-dividend date is 14 June 2024. Record date is 23 June 2024. Payment date is 09 August 2024.お知らせ • May 22Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024, at 09:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, the prc, beijing Chinaお知らせ • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024お知らせ • Mar 05Tong Ren Tang Technologies Co. Ltd. Receives Notice of Approval for Clinical Trial of MedicineTong Ren Tang Technologies Co. Ltd. announced that the pharmaceutical factory of the Company recently received the Notice of Approval for Clinical Trial of Medicine (Yao Wu Lin Chuang Shi Yan Pi Zhun Tong Zhi Shu) issued by the National Medical Products Administration. Details are as follows: Basic information of the medicine: Qishen Granules (Qi Can Ke Li) Applicant: Tong Ren Tang Technologies Co. Ltd.'s Pharmaceutical Factory. Category of registration: Registration category 1.1 of traditional Chinese medicines. Indications: Benefiting qi and warming yang, and promoting blood circulation and detoxication. Curing for the syndrome of chronic heart failure due to qi deficiency and blood stasis. Acceptance number: CXZL2300074. Notice number: 2024LP00491. Review conclusion: According to the Drug Administration Law of the People's Republic of China (<Zhong Hua Ren Min Gong He Guo Yao Pin Guan Li Fa >) /V Vaccine Administration Law of the People'sRepublic of China (Zhong Hua Ren Minong He Guo Yi Miao Guan Li Fa >) and relevant regulations, Qishen Granules (Qi Can Ke Li) was approved to use in clinical trial for chronic heart failure with reduced ejection fraction. Research and development of the medicine and related information. The Qishen Granules ("Qi Can Ke Li") applied for clinical trial by the pharmaceutical factory of the Company is a traditional Chinese medicine compound preparation, which is applied according to the registration category 1.1 of traditional Chinese medicines and is intended to be used for chronic heart failure syndrome of qi deficiency and bloodstasis. As at the date of this announcement, the Company has invested approximately RMB 7.8 million (unaudited) in the research and development of Qi Can Ke Li). Risk warning: In accordance with the requirements of the relevant laws and regulations on registration of medicine in the PRC, a clinical trial of medicine shall be performed upon receiving the approval for the clinical trial and the medicine shall be produced and marketed only upon being assessed and scrutinized by the National Medical Products Administration. Given its special nature and long cycle from clinical trials to production upon approval which involves many stages, the research and development of medicine are susceptible to many unpredictable factors. There are uncertainties in the progress and results of clinical trials and the future competitive landscape of the pharmaceutical market. Investors are advised to consider the risks involved and be cautious in making investment decisions.お知らせ • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.お知らせ • Jan 22Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesThe board (the "Board") of directors (the "Director(s)") of Tong Ren Tang Technologies Co. Ltd. announce that the extraordinary general meeting of the Company was held on 22 January 2024, approved the appointment of Mr. Di Shu Bing as an executive Director of the eighth session of the Board. Following the resignation of Mr. Gu Hai Ou as an executive Director, Mr. Di Shu Bing has been appointed as an executive Director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Mr. Di Shu Bing commence from the date of appointment (i.e. 22 January 2024) and until the end of this session of the Board, subject to re-elected at the end of the term. Mr. Di Shu Bing will not receive remuneration for his service as an executive Director. The Board announce that the Board resolved on 22 January 2024 to elect Mr. Di Shu Bing as the Chairman of the Board. On the same day, the Board also resolved to appoint Mr. Di Shu Bing as the chairman of the nomination committee of the Board and the chairman of the strategy and planning committee of the Board. The Board hereby announces that, Mr. Di Shu Bing was appointed as an authorized representative of the Company under the Rule 3.05 of the Hong Kong Listing Rules with effect from 22 January 2024.お知らせ • Dec 13Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Gu Hai Ou as Executive Director, Chairman of the Board, Chairman of the Nomination Committee, Chairman of the Strategy and Planning CommitteeOn 13 December 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Gu Hai Ou ("Mr. Gu"), informing the Board of his resignation from the positions as an executive Director, chairman of the Board, chairman of the nomination committee of the Board, chairman of the strategy and planning committee of the Board and the authorized representative, due to work adjustments. The above-mentioned resignation of Mr. Gu will take effect upon the new executive Director being elected by the shareholders of the Company (the "Shareholders") at the general meeting to be held. Mr. Gu has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange and the Shareholders. The Board further announces on 13 December 2023, proposal in relation to the appointment of Mr. Di Shu Bing ("Mr. Di") as the executive Director of the eighth Board of Directors of the Company, and to have the Board recommend his remuneration and authorize the Board to enter into a service contract with him. The Board therefore proposed to appoint Mr. Di as an executive Director in accordance with relevant laws and regulations and the articles of association of the Company. The proposed appointment of Mr. Di as an executive Director is subject to the approval by the Shareholders at the general meeting. Mr. Di Shu Bing (), aged 49, a senior accountant with a master degree of public administration. Mr. Di previously served as the finance supervisor of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, the deputy manager of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, a member of the Party Committee and the deputy general manager of Beijing Tong Ren Tang Commercial Investment Group, the assistant to the general manager and head of economic operation department of China Beijing Tong Ren Tang Group Co. Ltd., a director of Beijing Tong Ren Tang Health Industry Investment Co. Ltd., the chairman of Beijing Tong Ren Tang Traditional Chinese Medicine Formula Granules Investment Co. Ltd., a director of Beijing Tong Ren Tang Biological Product Development Co. Ltd., a director of Beijing Tong Ren Tang Cosmetics Co. Ltd., the vice chairman of Beijing Entrepreneurs Association and the vice chairman of Beijing Enterprise Confederation, the deputy head of the finance department, the deputy head and head of the investment management department, the secretary of the Party Committee, a director and the general manager of Beijing Tong Ren Tang Company Limited. Mr. Di currently serves as party secretary of the CPC Committee and chairman of Beijing Tong Ren Tang Company Limited, the deputy general manager of China Beijing Tong Ren Tang Group Co. Ltd. and the vice chairman of Beijing Pharmaceutical Profession Association.お知らせ • Aug 26Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. announced following the resignation of Mr. Wang Yu Wei as an executive director, Mr. Chen Jia Fu has been appointed as an executive director of the eighth session of the board of the company as approved by the Shareholders at the EGM. The terms of office of Mr. Chen Jia Fu commence from the date of appointment (that is 25 August 2023) and until the end of this session of the board, subject to re-elected at the end of the term. Mr. Chen Jia Fu will not receive remuneration for his service as an executive director. Change in board committee members: The board further announced that following the resignation of Mr. Wang Yu Wei as an executive Director, Mr. Chen Jia Fu has been appointed as a member of the strategy and planning committee of the board with effect from 25 August 2023.お知らせ • Aug 04Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2023 Results on Aug 24, 2023Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2023 results on Aug 24, 2023お知らせ • Jun 16+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Board ChangesOn 15 June 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Wang Yu Wei, informing the Board of Mr. Wang's application for resignation from the position as an executive Director and the general manager of the Company due to work changes. The resignation of Mr. Wang as an executive Director will take effect upon the new executive Director being elected by the shareholders of the Company at the general meeting to be held and his resignation as the General Manager has taken effect from 15 June 2023. The Board further announced that, on 15 June 2023, the Board proposed to appoint Mr. Chen Jia Fu as an executive Director and the General Manager. The proposed appointment of Mr. Chen as an executive Director is subject to the approval by the Shareholders at the general meeting. The proposed appointment of Mr. Chen as the General Manager has taken effect from 15 June 2023. Mr. Chen Jia Fu, aged 54, a pharmacist-in-charge and a licensed pharmacist with a postgraduate degree. He formerly served as the deputy secretary to the Party Committee of the Company, the secretary to the Disciplinary Inspection Committee of the Company, the chairman of the labour committee of the Company, and the deputy general manager of the Company. He used to work as the deputy general manager of Beijing Tong Ren Tang Company Limited and used to work as the chairman of the board, the secretary of general Party branch, the director and the general manager of Beijing Tong Ren Tang Pharmaceutical Co. Ltd. He currently serves as the secretary of the Party Committee of the Company and the General Manager.お知らせ • Feb 17Tong Ren Tang Technologies Co. Ltd. Announces Change of DirectorThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that the extraordinary general meeting (the "EGM") of the Company was held at No. 20 Nansanhuan Zhonglu, Fengtai District, Beijing, the People's Republic of China (the "PRC") at 9:30 a.m., on 16 February 2023 approve the appointment of Ms. Wang Chun Rui as a non-executive Director of the eighth session of the Board of the Company and the remuneration proposed by the Board, and to authorize the Board to enter into the service contract with Ms. Wang Chun Rui. Following the resignation of Ms. Guo Ya Qing as a non-executive director, Ms. Wang Chun Rui has been appointed as a non-executive director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Ms. Wang Chun Rui commence from the date of appointment (i.e. 16 February 2023) and until the end of this session of the Board, subject to re-elected at the end of the term. Ms. Wang Chun Rui will not receive remuneration for her service as a non-executive Director.業績と収益の成長予測OTCPK:TGRN.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20288,224580N/A690112/31/20277,563514N/A640212/31/20266,982455N/A933212/31/20256,4843961,4461,562N/A9/30/20256,7164141,4441,576N/A6/30/20256,9484321,4431,589N/A3/31/20257,104477642802N/A12/31/20247,260522-15916N/A9/30/20247,068586-516-366N/A6/30/20246,877651-873-747N/A3/31/20246,825620-211-97N/A12/31/20236,773590451554N/A9/30/20236,849611667797N/A6/30/20236,9246338841,041N/A3/31/20236,458608722882N/A12/31/20225,992583560724N/A9/30/20225,820546761909N/A6/30/20225,6495109621,095N/A3/31/20225,5255099191,064N/A12/31/20215,4005078771,033N/A9/30/20215,267509498793N/A6/30/20215,133511120552N/A3/31/20214,870489-103494N/A12/31/20204,607468-325436N/A9/30/20204,425387-1626N/A6/30/20204,242307323816N/A3/31/20204,359362553934N/A12/31/20194,4764187831,052N/A9/30/20194,604523N/A1,120N/A6/30/20194,731628N/A1,187N/A3/31/20194,895653N/A1,086N/A12/31/20185,060678N/A985N/A9/30/20185,054681N/A843N/A6/30/20185,047683N/A700N/A3/31/20185,036675N/A690N/A12/31/20175,025667N/A680N/A9/30/20174,882624N/A569N/A6/30/20174,739582N/A459N/A3/31/20174,702589N/A434N/A12/31/20164,665596N/A410N/A9/30/20164,546603N/A396N/A6/30/20164,426610N/A383N/A3/31/20164,247575N/A343N/A12/31/20154,067541N/A304N/A9/30/20153,915529N/A357N/A6/30/20153,764517N/A411N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TGRN.Fの予測収益成長率 (年間12.4% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: TGRN.Fの収益 ( 12.4% ) US市場 ( 18.5% ) よりも低い成長が予測されています。高成長収益: TGRN.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: TGRN.Fの収益 ( 7.8% ) US市場 ( 12.6% ) よりも低い成長が予測されています。高い収益成長: TGRN.Fの収益 ( 7.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TGRN.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 7.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/28 05:40終値2026/05/13 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tong Ren Tang Technologies Co. Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Yanyin ZhuChina International Capital Corporation LimitedZhu ChenCitic Securities Co., Ltd.Jun Zhou LiEverbright Securities Co. Ltd.2 その他のアナリストを表示
お知らせ • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.
お知らせ • Apr 27+ 1 more updateTong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026, at 10:00 China Standard Time. Location: no. 28 tiangui avenue, daxing district, beijing China
お知らせ • Mar 16Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026
お知らせ • Feb 06Tong Ren Tang Technologies Co. Ltd. Announces Appointment of Mr. Siu, Paul Yu Hay as Independent Non-Executive Director and Changes in Board Committee Composition, Effective February 6, 2026Tong Ren Tang Technologies Co. Ltd. announced that, following the extraordinary general meeting held on February 6, 2026, announced that, with effect from 6 February 2026, Mr. Siu, Paul Yu Hay has been appointed as an independent non-executive Director of the ninth session of the Board. The resignation of Mr. Li Siu Bun as an independent non-executive Director has also taken effect from the same date. Mr. Siu, Paul Yu Hay will enter into a director's service contract with the Company for a term commencing from the date of his appointment (i.e. 6 February 2026) and until the end of this session of the Board, subject to re-election at the end of the term. The resignation of Mr. Li Siu Bun as the chairman of the Audit Committee and a member of each of the Remuneration Committee and the Strategy and Planning Committee has also taken effect on 6 February 2026. The Board further resolved on 6 February 2026 to appoint Mr. Siu, Paul Yu Hay as the chairman of the Audit Committee, and a member of the Remuneration Committee and the Strategy and Planning Committee, all with effect from the same date.
お知らせ • Jan 14Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Li Siu Bun from the Positions as an Independent Non-Executive Director, Chairman of the Audit Committee of the Board and A Member of Each of the Remuneration Committee of the Board and the Strategy and Planning CommitteeOn 13 January 2026, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Li Siu Bun, informing the Board of his resignation from the positions as an independent non-executive Director, chairman of the audit committee of the Board and a member of each of the remuneration committee of the Board and the strategy and planning committee of the Board due to work adjustments. The aforesaid resignation of Mr. Li will take effect upon the new independent non-executive Director being elected by the shareholders of the Company at the general meeting to be held in due course.
お知らせ • Dec 31Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. held an extraordinary general meeting on December 30, 2025, at which the appointment of Ms. Du Xin as a non-executive Director of the ninth session of the Board of the Company was approved and confirmed. The resignation of Mr. Chen Fei as a non-executive Director has also taken effect from the same date. Ms. Du Xin will enter into a director’s service contract with the Company for a term commencing from the date of her appointment, December 30, 2025, and until the end of this session of the Board, subject to re-election at the end of the term. Ms. Du Xin’s remuneration for her services as a non-executive Director is nil, which is determined by the Board with reference to the recommendation from the remuneration committee of the Board, having taken into account her duties and responsibilities with the Company and the prevailing market conditions. As at the date of this announcement, Ms. Du Xin’s biographical details remain unchanged from those stated in the circular dated December 1, 2025 save as disclosed in this announcement. As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza, Mr. Zhan Yuan Jing and Mr. Li Siu Bun as independent non-executive Directors, and Mr. Zhu Dong Sheng as employee Director.
お知らせ • Nov 28+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Executive Changes, Effective November 28, 2025The board of directors (the "Board") of Tong Ren Tang Technologies Co. Ltd. (the "Company") hereby announces that, with effect from 28 November 2025, (i) Mr. Li Yijun ("Mr. Li") has resigned as the company secretary of the Company, the secretary of the Board, and the authorised representative (the "Authorised Representative") under the Rule 3.05 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") of the Company due to his family reasons; and (ii) Ms. Yung Mei Yee ("Ms. Yung") has ceased to serve as the agent for acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent") due to work adjustment. Both Mr. Li and Ms. Yung have confirmed that they have no disagreement with the Board and there is no matter relating to their resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board also announced that, with effect from 28 November 2025, (i) Ms. Ma Wing Yee ("Ms. Ma") has been appointed as the company secretary of the Company, the Authorised Representative and the Process Agent; and (ii) Mr. Han Guan Zhao ("Mr. Han") has been appointed as the secretary of the Board. Ms. Ma is an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited and has over 10 years of experience in corporate governance and company secretarial practice in listed companies on the Stock Exchange. She is currently the company secretary or joint company secretary of a few listed companies on the Stock Exchange. Ms. Ma obtained a bachelor's degree in Arts from the University of Hong Kong. She is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Mr. Han, aged 46, is a corporate legal adviser with a postgraduate qualification. He formerly served as the office senior legal affairs manager and manager of the legal affairs department of COFCO Feed Co. Ltd. Mr. Han joined the Company in December 2019, he currently serves as deputy general manager, general legal counsel and chief compliance officer of the Company.
お知らせ • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2025 Results on Aug 26, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Jun 12+ 1 more updateTong Ren Tang Technologies Co. Ltd. Approves Final Dividend for the Year Ended 31 December 2024, Payable on 11 August 2025Tong Ren Tang Technologies Co. Ltd. announced at annual general meeting held on June 12, 2025, the shareholders approved the proposal of payment of a final dividend of RMB 0.18 (equivalent to HKD 0.196600) (tax inclusive) per share for the year ended 31 December 2024, will be paid on 11 August 2025 to the Shareholders whose names appear on the registers of members of the Company on 23 June 2025.
お知らせ • May 20Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025, at 13:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, beijing, prc., China
お知らせ • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025
お知らせ • Oct 29Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Yung Mei Yee as Joint Company SecretaryThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that, due to work adjustment, Ms. Yung Mei Yee ("Ms. Yung") has resigned as the joint company secretary of the Company with effect from 29 October 2024. Ms. Yung has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Following the resignation of Ms. Yung, Mr. Li Yijun, the other Joint Company Secretary, who possess the qualifications and experience of company secretary as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, will remain in office and act as the sole company secretary of the Company with effect from 29 October 2024.
お知らせ • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2024 Results on Aug 30, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Jun 13+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Payment of Final Dividend for the Year Ended 31 December 2023, Payable on 09 August 2024Tong Ren Tang Technologies Co. Ltd. announced that at its AGM held on June 12, 2024, To consider and, if thought fit, to approve the proposal of payment of a final dividend of RMB 0.18 (tax inclusive) per share for the year ended 31 December 2023. Ex-dividend date is 14 June 2024. Record date is 23 June 2024. Payment date is 09 August 2024.
お知らせ • May 22Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024, at 09:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, the prc, beijing China
お知らせ • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024
お知らせ • Mar 05Tong Ren Tang Technologies Co. Ltd. Receives Notice of Approval for Clinical Trial of MedicineTong Ren Tang Technologies Co. Ltd. announced that the pharmaceutical factory of the Company recently received the Notice of Approval for Clinical Trial of Medicine (Yao Wu Lin Chuang Shi Yan Pi Zhun Tong Zhi Shu) issued by the National Medical Products Administration. Details are as follows: Basic information of the medicine: Qishen Granules (Qi Can Ke Li) Applicant: Tong Ren Tang Technologies Co. Ltd.'s Pharmaceutical Factory. Category of registration: Registration category 1.1 of traditional Chinese medicines. Indications: Benefiting qi and warming yang, and promoting blood circulation and detoxication. Curing for the syndrome of chronic heart failure due to qi deficiency and blood stasis. Acceptance number: CXZL2300074. Notice number: 2024LP00491. Review conclusion: According to the Drug Administration Law of the People's Republic of China (<Zhong Hua Ren Min Gong He Guo Yao Pin Guan Li Fa >) /V Vaccine Administration Law of the People'sRepublic of China (Zhong Hua Ren Minong He Guo Yi Miao Guan Li Fa >) and relevant regulations, Qishen Granules (Qi Can Ke Li) was approved to use in clinical trial for chronic heart failure with reduced ejection fraction. Research and development of the medicine and related information. The Qishen Granules ("Qi Can Ke Li") applied for clinical trial by the pharmaceutical factory of the Company is a traditional Chinese medicine compound preparation, which is applied according to the registration category 1.1 of traditional Chinese medicines and is intended to be used for chronic heart failure syndrome of qi deficiency and bloodstasis. As at the date of this announcement, the Company has invested approximately RMB 7.8 million (unaudited) in the research and development of Qi Can Ke Li). Risk warning: In accordance with the requirements of the relevant laws and regulations on registration of medicine in the PRC, a clinical trial of medicine shall be performed upon receiving the approval for the clinical trial and the medicine shall be produced and marketed only upon being assessed and scrutinized by the National Medical Products Administration. Given its special nature and long cycle from clinical trials to production upon approval which involves many stages, the research and development of medicine are susceptible to many unpredictable factors. There are uncertainties in the progress and results of clinical trials and the future competitive landscape of the pharmaceutical market. Investors are advised to consider the risks involved and be cautious in making investment decisions.
お知らせ • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.
お知らせ • Jan 22Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesThe board (the "Board") of directors (the "Director(s)") of Tong Ren Tang Technologies Co. Ltd. announce that the extraordinary general meeting of the Company was held on 22 January 2024, approved the appointment of Mr. Di Shu Bing as an executive Director of the eighth session of the Board. Following the resignation of Mr. Gu Hai Ou as an executive Director, Mr. Di Shu Bing has been appointed as an executive Director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Mr. Di Shu Bing commence from the date of appointment (i.e. 22 January 2024) and until the end of this session of the Board, subject to re-elected at the end of the term. Mr. Di Shu Bing will not receive remuneration for his service as an executive Director. The Board announce that the Board resolved on 22 January 2024 to elect Mr. Di Shu Bing as the Chairman of the Board. On the same day, the Board also resolved to appoint Mr. Di Shu Bing as the chairman of the nomination committee of the Board and the chairman of the strategy and planning committee of the Board. The Board hereby announces that, Mr. Di Shu Bing was appointed as an authorized representative of the Company under the Rule 3.05 of the Hong Kong Listing Rules with effect from 22 January 2024.
お知らせ • Dec 13Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Gu Hai Ou as Executive Director, Chairman of the Board, Chairman of the Nomination Committee, Chairman of the Strategy and Planning CommitteeOn 13 December 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Gu Hai Ou ("Mr. Gu"), informing the Board of his resignation from the positions as an executive Director, chairman of the Board, chairman of the nomination committee of the Board, chairman of the strategy and planning committee of the Board and the authorized representative, due to work adjustments. The above-mentioned resignation of Mr. Gu will take effect upon the new executive Director being elected by the shareholders of the Company (the "Shareholders") at the general meeting to be held. Mr. Gu has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange and the Shareholders. The Board further announces on 13 December 2023, proposal in relation to the appointment of Mr. Di Shu Bing ("Mr. Di") as the executive Director of the eighth Board of Directors of the Company, and to have the Board recommend his remuneration and authorize the Board to enter into a service contract with him. The Board therefore proposed to appoint Mr. Di as an executive Director in accordance with relevant laws and regulations and the articles of association of the Company. The proposed appointment of Mr. Di as an executive Director is subject to the approval by the Shareholders at the general meeting. Mr. Di Shu Bing (), aged 49, a senior accountant with a master degree of public administration. Mr. Di previously served as the finance supervisor of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, the deputy manager of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, a member of the Party Committee and the deputy general manager of Beijing Tong Ren Tang Commercial Investment Group, the assistant to the general manager and head of economic operation department of China Beijing Tong Ren Tang Group Co. Ltd., a director of Beijing Tong Ren Tang Health Industry Investment Co. Ltd., the chairman of Beijing Tong Ren Tang Traditional Chinese Medicine Formula Granules Investment Co. Ltd., a director of Beijing Tong Ren Tang Biological Product Development Co. Ltd., a director of Beijing Tong Ren Tang Cosmetics Co. Ltd., the vice chairman of Beijing Entrepreneurs Association and the vice chairman of Beijing Enterprise Confederation, the deputy head of the finance department, the deputy head and head of the investment management department, the secretary of the Party Committee, a director and the general manager of Beijing Tong Ren Tang Company Limited. Mr. Di currently serves as party secretary of the CPC Committee and chairman of Beijing Tong Ren Tang Company Limited, the deputy general manager of China Beijing Tong Ren Tang Group Co. Ltd. and the vice chairman of Beijing Pharmaceutical Profession Association.
お知らせ • Aug 26Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. announced following the resignation of Mr. Wang Yu Wei as an executive director, Mr. Chen Jia Fu has been appointed as an executive director of the eighth session of the board of the company as approved by the Shareholders at the EGM. The terms of office of Mr. Chen Jia Fu commence from the date of appointment (that is 25 August 2023) and until the end of this session of the board, subject to re-elected at the end of the term. Mr. Chen Jia Fu will not receive remuneration for his service as an executive director. Change in board committee members: The board further announced that following the resignation of Mr. Wang Yu Wei as an executive Director, Mr. Chen Jia Fu has been appointed as a member of the strategy and planning committee of the board with effect from 25 August 2023.
お知らせ • Aug 04Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2023 Results on Aug 24, 2023Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2023 results on Aug 24, 2023
お知らせ • Jun 16+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Board ChangesOn 15 June 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Wang Yu Wei, informing the Board of Mr. Wang's application for resignation from the position as an executive Director and the general manager of the Company due to work changes. The resignation of Mr. Wang as an executive Director will take effect upon the new executive Director being elected by the shareholders of the Company at the general meeting to be held and his resignation as the General Manager has taken effect from 15 June 2023. The Board further announced that, on 15 June 2023, the Board proposed to appoint Mr. Chen Jia Fu as an executive Director and the General Manager. The proposed appointment of Mr. Chen as an executive Director is subject to the approval by the Shareholders at the general meeting. The proposed appointment of Mr. Chen as the General Manager has taken effect from 15 June 2023. Mr. Chen Jia Fu, aged 54, a pharmacist-in-charge and a licensed pharmacist with a postgraduate degree. He formerly served as the deputy secretary to the Party Committee of the Company, the secretary to the Disciplinary Inspection Committee of the Company, the chairman of the labour committee of the Company, and the deputy general manager of the Company. He used to work as the deputy general manager of Beijing Tong Ren Tang Company Limited and used to work as the chairman of the board, the secretary of general Party branch, the director and the general manager of Beijing Tong Ren Tang Pharmaceutical Co. Ltd. He currently serves as the secretary of the Party Committee of the Company and the General Manager.
お知らせ • Feb 17Tong Ren Tang Technologies Co. Ltd. Announces Change of DirectorThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that the extraordinary general meeting (the "EGM") of the Company was held at No. 20 Nansanhuan Zhonglu, Fengtai District, Beijing, the People's Republic of China (the "PRC") at 9:30 a.m., on 16 February 2023 approve the appointment of Ms. Wang Chun Rui as a non-executive Director of the eighth session of the Board of the Company and the remuneration proposed by the Board, and to authorize the Board to enter into the service contract with Ms. Wang Chun Rui. Following the resignation of Ms. Guo Ya Qing as a non-executive director, Ms. Wang Chun Rui has been appointed as a non-executive director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Ms. Wang Chun Rui commence from the date of appointment (i.e. 16 February 2023) and until the end of this session of the Board, subject to re-elected at the end of the term. Ms. Wang Chun Rui will not receive remuneration for her service as a non-executive Director.